Abstract
The concept of oligometastatic disease (OMD) was first introduced in 1995 by Hellman and Weichselbaum and described as stage of transition between localised and widespread metastatic disease. The presence of OMD in esophago-gastric (OG) cancer remains controversial. Historically, most experts believe that OG cancer is systemic disease from the outset. Summary More recently, there is emerging data indicating improved outcomes in patients with OG cancer and oligo-metastatic disease. The present manuscript focuses on reviewing the emerging evidence in management of metastatic OG cancer with OMD and highlighting the direction of future research. Multiple retrospective and at least 2 Phase II retrospective studies have reported on improved outcomes in patients with metastatic OG cancer and oligometastatic disease. There is indication of improved outcome with combined systemic and local therapy (surgery or radiation). Further research should include phase III randomised studies to identify the optimal management algorithm in these group of patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
